No Data
Contract research organizations concept rises, Joinn Laboratories (06127) rises by 5.11%, institutions say CXO sector is expected to benefit from the recovery of overseas research and development demand.
Jinwu Financial News | The concept of contract research organizations has risen across the board, with joinn laboratories (06127) up 5.11%, tigermed (03347) up 4.33%, frontage (01521) up 2%, pharmaron (03759) up 1.84%, and wuxi bio (02269) up 0.79%. Zhongtai reported that the bank believes that as the medical insurance fund prepayment system continues to deepen and improve, and the supporting DRG/DIP system is continuously implemented in various provinces and cities, the long-term "triangle debt" relationship among hospitals, pharmaceutical companies, and medical insurance persists, and the "zero markup policy on pharmaceuticals" compresses hospital profitability.
Trending Industry Today: WUXI APPTEC Leads Losses In CRO Stocks
Joinn Laboratories (603127.SH): Cumulative repurchase of 0.2806% A-share shares.
On November 1, Gelunhui reported that Joinn Laboratories (603127.SH) announced that as of October 31, 2024, the company has cumulatively repurchased 2,103,100 shares of A shares through centralized auction trading, accounting for 0.2806% of the total shares on the date of this announcement. The highest repurchase price was RMB 18.15 per share, and the lowest repurchase price was RMB 13.20 per share, with a total amount of RMB 33,195,984.40 (excluding transaction costs).
Joinn Laboratories' Q3 Profit Slides 58%
Zhaoyan Pharmaceutical: Zhaoyan New Pharmaceutical Report for the Third Quarter of 2024
Zhaoyan New Pharmaceutical Report for the Third Quarter of 2024
Earnings Working Against Joinn Laboratories(China)Co.,Ltd.'s (SHSE:603127) Share PriceNo Data
No Data
